I would trust my stock broker: The Drug is Dangerous!

Although it is efficacious, Osphena has some major drawbacks with regards to its safety and use. Uncommon and possible side effects of the drug include stroke, blood clots, and endometrial cancer (cancer of the uterus). Common side effects include hot flashes, discharge, muscle spams, and increased sweating. While this therapy may replace standard estrogen therapy, it is dangerous. In addition, it is far from an equivalent to "female Viagra".

 

Sell Osphena Stock. Buy this one:

Bremelanotide - Palatin

Palatin (NYSEMKTTN) recently completed end-of-phase II meetings with the FDA, and has reached preliminary agreement on key aspects of the Phase III pivotal trial. This includes the FSD patient population, the primary and key secondary efficacy endpoints, design, dosing, and safety monitoring. Since the FDA has been hard on efficacy data presented for the FSD indication, it's encouraging to hear their close involvement with the design of bremelanotide's pivotal trial.

Phase II data and discussion from a previous note (link):

The Company is testing bremelanotide, a peptide melanocortin receptor agonist, in patients with FSD. Bremalanotide works via activation of melanocortin receptors in the central nervous system, and is intended for on-demand use approximately an hour prior to anticipated sexual activity. In the first quarter of 2013, Palatin released top-line data for their Phase IIb, at-home clinical trial in patients with female sexual dysfunction.

The trial hit on the primary and key secondary endpoints, a major success, demonstrating a good safety profile for bremalanotide and statistically significant increases in the number of Satisfying Sexual Events (SSE) versus placebo. The most common adverse reactions with incidence over 5% among bremalanotide users at any dose included nausea, flushing, and headache. The FDA approved a Phase III trial design with bremalanotide, and the Company could start the trial as early as Q4 2013.

The drug's safety and tolerability has been adequate up to this point, and should be adequate for approval after the trial. This is because the cardiovascular risk concerns will be studied closely through patient blood pressure monitoring.

The FDA is expected to finalize the design of the trial before the end of the year. Patient screening is also expected to start before the end of the year. Official estimates for interim data aren't available, although the conclusion of the enrollment process should give us a lot more to work with. Investor attention is expected to increase significantly as we approach potential data releases for the pivotal trials, since they will be major catalysts for shares of PTN.

 

YOu are all screwed.
See article
http://www.nj.com/business/index.ssf/2014/04/nj_biotech_firm_moves_ahead_with_its_female_viagara_drug.html

 

One of our MAJOR speakers is very HIGH on this drug. He said Osphena is a good drug, but Shionogi shouldn't have put all their eggs in one basket as it won't really take off for years if ever.

 

First of all, you can't buy or sell Shionogi stock unless you are on the Tokyo Stock Exchange.

Second, a drug that increases female sex drive would help Osphena because the market would grow.

 

Just like Duavee would help Osphena? Stop drinking the Koolaid. This drug will NOT take off for years if ever. Layoffs will come soon after this new guy realizes this which means a few weeks. He's Actavis. Check his history.